Sanofi Buys TargeGen And Its Lead Myelofibrosis Drug For $75 Million Upfront
This article was originally published in The Pink Sheet Daily
Executive Summary
It's another earn-out based exit for venture capital, but TargeGen's backers could realize more than five times their initial investment if all milestones are achieved.
You may also be interested in...
The Bell Tolls For Fedratinib In A Setback For Sanofi’s Oncology Portfolio
The company has halted clinical trials testing its Phase III JAK2 inhibitor fedratinib after determining that the risks of treatment outweigh the benefit after cases of the neurological condition Wernicke’s encephalopathy emerged in patients.
Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term
The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.
Deals Of The Week: Sanofi/TargeGen, Arena/Eisai, GSK/Genmab ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.